|
KMID : 1148920220560060313
|
|
Nuclear Medicine and Molecular Imaging
2022 Volume.56 No. 6 p.313 ~ p.322
|
|
|
Preparation of Patient Doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 with Carrier Added (CA) and No Carrier Added (NCA) 177Lu
|
|
Nanabala Raviteja
Pillai Maroor Raghavan Ambikalmajan
Gopal Buvaneswari
|
|
|
Abstract
|
|
|
Purpose: [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 used for targeted radionuclide therapy are very often prepared in the hospital radiopharmacy. The preparation parameters vary depending upon the specific activity of the 177Lu used. The aim of this study was to develop optimized protocols to be used in the nuclear medicine department for the preparation of patient doses of the above radiopharmaceuticals.
Method: 177Lu (CA and NCA) were used for radiolabeling DOTATATE and PSMA-617. Parameters studied are 177Lu of different specific activity and different peptide concentrations and two different buffer systems. Paper and thin layer chromatography systems were used for estimating the radiochemical yield as well as radiochemical purity. Solid-phase extraction was used for the purification of the labeled tracers.
Results: [177Lu]Lu-DOTATATE was prepared with CA 177Lu (n?=?13) and NCA177Lu (n?=?6). Four batches each of [177Lu]Lu-PSMA-617 were prepared using CA and NCA 177Lu. Radiochemical yields?>?80% and final product with less than?
Conclusion: Robust protocols for the preparation of clinical doses of [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617 were developed and used for the preparation of clinical doses. The quality of the SPECT images of both the tracers are consistent with the expected uptake in respective diseases.
|
|
|
KEYWORD
|
|
|
[177Lu]Lu-DOTATATE, [177Lu]Lu-PSMA-617, Neuroendocrine tumours, Prostate cancer, Targeted radionuclide therapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|